Roche's Hemlibra has earned a a fast-track review by the U.S. Food and Drug Administration for treatment of children and adults with hemophilia A without factor VIII inhibitors.
An approval is expected Oct. 4. Back in April, the drug had received breakthrough therapy designation for the medicine to be used in people who have not yet developed resistance to conventional treatments.
Read the Reuters report